The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.
The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.